Cytek Biosciences, Inc. will announce its financial results for the second quarter of 2026 after market close on Wednesday, August 5, 2026. The company’s management will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to review the results, business developments, and outlook. This announcement provides investors with an opportunity to assess the company's performance and strategic direction for the period.

The live audio webcast will be accessible through the "Investors" section of Cytek Biosciences' website at investors.cytekbio.com. Investors and interested parties can listen to the discussion and gain insights into the company's operational progress and future expectations.

Key Event Details

Cytek Biosciences is a cell analysis solutions company that provides high-resolution, high-content, and high-sensitivity cell analysis tools. Its offerings include the Full Spectrum Profiling (FSP) technology, instruments such as the Cytek Aurora and Northern Lights systems, and reagents and software. The company is headquartered in Fremont, California, and serves a global customer base.

In addition to regulatory filings, Cytek Biosciences uses its website, LinkedIn page, and X account to disseminate material information. The company emphasizes that these channels are used to comply with Regulation FD and other disclosure requirements, advising investors to monitor them for updates.

Cytek Biosciences has opened a new innovation center in Bellevue, Washington, marking the relocation of its previous Seattle-area operations to a dedicated facility designed to support research and development (R&D) while strengthening collaboration and customer engagement. The new site serves as a sole tenant hub for innovation and technical excellence, bringing together key capabilities under one roof.

The facility includes R&D laboratories, dedicated areas for instrument service training and customer demonstrations, and assembly and testing operations. By positioning itself within a region known for its concentration of global technology companies, Cytek aims to leverage a dynamic ecosystem to support ongoing scientific advancements and accelerate product development.

Strategic Investment and Infrastructure

The Bellevue innovation center reflects Cytek’s strategic investment in an environment that fosters collaboration. The design enables R&D teams to develop the next generation of technologies and addresses evolving needs in research and clinical applications. The site incorporates employee-focused amenities and collaborative workspaces intended to encourage creativity and cross-functional teamwork.

Leadership Perspective

Wenbin Jiang, Ph.D., CEO of Cytek Biosciences, emphasized the significance of the new facility. "The Bellevue innovation center represents an important step in strengthening our ability to develop and deliver new technologies," Jiang said. "It highlights our commitment to building the infrastructure needed to advance scientific discovery and enable meaningful innovation."

The opening of the Bellevue facility underscores Cytek’s continued investment in infrastructure that supports its long-term growth and reinforces its efforts to advance high-dimensional cell analysis through innovation, training, and customer support.